• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  C. Thieblemont, B. Altmann, F. Frontzek, Loïc Renaud, L. Chartier, et al.. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis.. Blood Advances, 2023, BLOOD ADVANCES, 7 (15), p. 3968-3977. ⟨10.1182/bloodadvances.2022008888⟩. ⟨hal-04322322⟩
• 
  Antoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, Pierre Decazes, Alexandra Zduniak, et al.. High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock. Clinical Nutrition ESPEN, 2023, 55, pp.373-383. ⟨10.1016/j.clnesp.2023.04.007⟩. ⟨hal-04112173⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23, pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
• 
  Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
• 
  Pierre Decazes, Samy Ammari, Antoine de Prévia, Léo Mottay, Littisha Lawrance, et al.. Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs. Diagnostics, 2023, 13 (2), pp.205. ⟨10.3390/diagnostics13020205⟩. ⟨hal-04175332⟩
• 
  Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩
• 
  M Tonneau, R Nebbache, A Larnaudie, S Thureau, Y Pointreau, et al.. Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy. Cancer/Radiothérapie, 2024, 28 (1), pp.83-92. ⟨10.1016/j.canrad.2023.03.004⟩. ⟨hal-04441453⟩
• 
  Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, et al.. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. npj Breast Cancer, 2017, 3 (1), pp.4. ⟨10.1038/s41523-017-0005-y⟩. ⟨cea-04501580⟩
• 
  Pierre Decazes, Samy Ammari, Younes Belkouchi, Léo Mottay, Littisha Lawrance, et al.. Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer. Journal for Immunotherapy of Cancer, 2023, 11 (9), pp.e007315. ⟨10.1136/jitc-2023-007315⟩. ⟨hal-04287256⟩
• 
  Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
• 
  Blandine Truffault, David Bourhis, Anne Chaput, Jérémie Calais, Philippe Robin, et al.. Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse : Impact of Treatment Position and Images Registration Method. Frontiers in Medicine, 2020, 7, pp.218. ⟨10.3389/fmed.2020.00218⟩. ⟨hal-02922556⟩
• 
  Jennifer Le Guevelou, Colin Debaigt, Esma Saada-Bouzid, Julien Viotti, Nazim Khalladi, et al.. Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.. BMJ Open, 2020, BMJ Open, 10, pp.e038391. ⟨10.1136/bmjopen-2020-038391⟩. ⟨hal-04346738⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2023, 29 (10), pp.2593-2601. ⟨10.1038/s41591-023-02572-5⟩. ⟨hal-04212634⟩
• 
  Brice Paquette, Dewi Vernerey, Bruno Chauffert, Sandrine Dabakuyo, Loic Feuvret, et al.. Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma. Cancer Medicine, 2016, 5 (8), pp.1753-1764. ⟨10.1002/cam4.734⟩. ⟨hal-03036055⟩
• 
  Anne‐sophie Baudry, Sonya Yakimova, Anne Congard, Aurélie Untas, Séverine Guiu, et al.. Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress. Psycho-Oncology, 2022, 31 (5), pp.848-855. ⟨10.1002/pon.5876⟩. ⟨hal-03771024⟩
• 
  Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier Chinot, Maryline Barrie, Luc Taillandier, et al.. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23 (5), pp.524-e44. ⟨10.1634/theoncologist.2017-0689⟩. ⟨hal-01727451⟩

104

405